Q-omics provides the consensus-scored RPS6P26 profile across patient tissues and cancer cell-line models. RPS6P26 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS6P26 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RPS6P26 RNA expression shows 9,252 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight ACC, COAD, and READ as cancer lineages where RPS6P26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS6P26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS6P26 survival associations across molecular data types. RPS6P26 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS6P26 RNA expression–survival associations across cancer types. High RPS6P26 expression shows unfavorable associations in ACC and CESC, but favorable associations in SKCM, COAD, UCEC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS6P26 RNA expression.
This table summarizes RPS6P26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS6P26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS6P26 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, KICH and KIRC. The COAD box plot shows higher RPS6P26 RNA expression in tumor versus normal tissue (log2 FC = +1.228, t-test p < 0.001).
This table shows molecular features associated with RPS6P26 in patient tissues and cancer cell lines. In patient samples, RPS6P26 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
